Compare CTKB & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | LXRX |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.3M | 660.9M |
| IPO Year | 2021 | 2000 |
| Metric | CTKB | LXRX |
|---|---|---|
| Price | $4.54 | $1.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $5.63 | $4.15 |
| AVG Volume (30 Days) | 489.1K | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,015,000.00 | $49,803,000.00 |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.67 | ★ 60.24 |
| 52 Week Low | $2.37 | $0.51 |
| 52 Week High | $6.18 | $1.95 |
| Indicator | CTKB | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 62.13 |
| Support Level | $4.00 | $1.07 |
| Resistance Level | $4.60 | N/A |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 43.69 | 76.74 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.